
USFDA17 Nov 2026, 07:40 pm
IGI Submits IND for ISB 2301 to US FDA
AI Summary
Ichnos Glenmark Innovation (IGI), a subsidiary of Glenmark Pharmaceuticals, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301. This is a first-in-class multispecific immune cell activator designed to target solid tumors by engaging T cells and natural killer (NK) cells. ISB 2301 targets three tumor-associated antigens and combines five binding specificities. IGI plans to initiate a Phase 1 clinical trial for ISB 2301 in patients with solid tumors in 2027. The drug was engineered using IGI's proprietary BEAT® Multispecific Platform.
Key Highlights
- IGI submitted IND application to US FDA for novel oncology drug ISB 2301.
- ISB 2301 is a first-in-class multispecific immune cell activator for solid tumors.
- Phase 1 clinical trial in solid tumor patients planned for 2027.
- Drug targets three tumor-associated antigens and engages T and NK cells.
Price Impact
More from GLENMARK